USD
+$0.00
(+0.00%
)At Close (As of Sep 5, 2025)
$16.79M
Market Cap
-
P/E Ratio
-1.19
EPS
$1.27
52 Week High
$0.14
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$40M |
Total Revenue | $20M |
Cost Of Revenue | $3.4M |
Costof Goods And Services Sold | $3.4M |
Operating Income | -$62M |
Selling General And Administrative | $22M |
Research And Development | $60M |
Operating Expenses | $22M |
Investment Income Net | - |
Net Interest Income | $1.7M |
Interest Income | $1.7M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.4M |
Income Before Tax | -$60M |
Income Tax Expense | -$60M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$60M |
Comprehensive Income Net Of Tax | - |
Ebit | -$60M |
Ebitda | -$57M |
Net Income | -$60M |
Field | Value (USD) |
---|---|
Total Assets | $30M |
Total Current Assets | $24M |
Cash And Cash Equivalents At Carrying Value | $18M |
Cash And Short Term Investments | $18M |
Inventory | - |
Current Net Receivables | $2.9M |
Total Non Current Assets | $6.6M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $925K |
Other Current Assets | $3.1M |
Other Non Current Assets | - |
Total Liabilities | $58M |
Total Current Liabilities | $16M |
Current Accounts Payable | $2.1M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $3.5M |
Total Non Current Liabilities | $42M |
Capital Lease Obligations | $2.5M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $2.5M |
Other Current Liabilities | $6.8M |
Other Non Current Liabilities | $318K |
Total Shareholder Equity | -$28M |
Treasury Stock | - |
Retained Earnings | -$306M |
Common Stock | $41K |
Common Stock Shares Outstanding | $41M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$60M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $3.4M |
Capital Expenditures | $123K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$123K |
Cashflow From Financing | $344K |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$60M |
Field | Value (USD) |
---|---|
Gross Profit | -$40M |
Total Revenue | $20M |
Cost Of Revenue | $3.4M |
Costof Goods And Services Sold | $3.4M |
Operating Income | -$62M |
Selling General And Administrative | $22M |
Research And Development | $60M |
Operating Expenses | $22M |
Investment Income Net | - |
Net Interest Income | $1.7M |
Interest Income | $1.7M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $3.4M |
Income Before Tax | -$60M |
Income Tax Expense | -$60M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$60M |
Comprehensive Income Net Of Tax | - |
Ebit | -$60M |
Ebitda | -$57M |
Net Income | -$60M |
Field | Value |
---|---|
Ex Dividend Date | 2023-03-08 |
Declaration Date | None |
Record Date | None |
Payment Date | None |
Amount | 0.36147078 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. The company is headquartered in Philadelphia, Pennsylvania.